A new study reveals the rising burden of liver cancer, highlighting the significant impact of metabolic risk factors like ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

This development has become especially prominent in China, where new research reveals a sharp rise in cancer cases linked to obesity within this age group. As lifestyles evolve and obesity rates ...

More than 180 million people live with obesity in China, which has a population of 1.4 billion. According to Chinese business news website Yicai, a dose of four Wegovy injections will cost 1,400 ...

The company had previously said it is focused on second- and third-generation opportunities in the space, such as oral versions as well as those with the potential to treat obesity-related conditions.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity. The Danish ...